Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis

Evan Der, Saritha Ranabothu, Hemant Suryawanshi, Kemal M. Akat, Robert Clancy, Pavel Morozov, Manjunath Kustagi, Mareike Czuppa, Peter Izmirly, H. Michael Belmont, Tao Wang, Nicole Jordan, Nicole Bornkamp, Janet Nwaukoni, July Martinez, Beatrice Goilav, Jill P. Buyon, Thomas Tuschl, Chaim Putterman

Research output: Contribution to journalArticlepeer-review

160 Scopus citations

Abstract

Lupus nephritis is a leading cause of mortality among systemic lupus erythematosus (SLE) patients, and its heterogeneous nature poses a significant challenge to the development of effective diagnostics and treatments. Single cell RNA sequencing (scRNA-seq) offers a potential solution to dissect the heterogeneity of the disease and enables the study of similar cell types distant from the site of renal injury to identify novel biomarkers. We applied scRNA-seq to human renal and skin biopsy tissues and demonstrated that scRNA-seq can be performed on samples obtained during routine care. Chronicity index, IgG deposition, and quantity of proteinuria correlated with a transcriptomic-based score composed of IFN-inducible genes in renal tubular cells. Furthermore, analysis of cumulative expression profiles of single cell keratinocytes dissociated from nonlesional, non–sun-exposed skin of patients with lupus nephritis also revealed upregulation of IFN-inducible genes compared with keratinocytes isolated from healthy controls. This indicates the possible use of scRNA-seq analysis of skin biopsies as a biomarker of renal disease. These data support the potential utility of scRNA-seq to provide new insights into the pathogenesis of lupus nephritis and pave the way for exploiting a readily accessible tissue to reflect injury in the kidney.

Original languageEnglish
Article numbere93009
JournalJCI insight
Volume2
Issue number9
DOIs
StatePublished - 4 May 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 American Society for Clinical Investigation. All rights reserved.

Funding

This work was supported by the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network. AMP is a public-private partnership created to develop new ways of identifying and validating promising biological targets for diagnostics and drug development (http://fnih.org/what-we-do/ current-research-programs/amp-ra-sle). Funding was provided by grants from the NIH (UH2-AR067676, UH2-AR067677, UH2-AR067679, UH2-AR067681, UH2-AR067685, UH2-AR067688, UH2-AR067689, UH2-AR067690, UH2-AR067691, UH2-AR067694, and UM2-AR067678). We would like to thank M. Yam-aji for providing valuable comments during the preparation of the manuscript, and D. Schwartz, J. Pullman, and M. Wu for scoring the renal biopsy histology.

FundersFunder number
National Institutes of HealthUH2-AR067677, UH2-AR067688, UH2-AR067689, UH2-AR067679, UH2-AR067685, UH2-AR067676, UH2-AR067691, UH2-AR067681, UH2-AR067694, UH2-AR067690
National Institute of Arthritis and Musculoskeletal and Skin DiseasesUM2AR067678

    Fingerprint

    Dive into the research topics of 'Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis'. Together they form a unique fingerprint.

    Cite this